Accretion Pharmaceuticals Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Accretion Pharmaceuticals Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹101
Per ShareLot Size
1200 Shares
Minimum Investment
₹1,21,200
Issue Size
₹29.75 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
43.7%
QIB Quota
12.6%
NII Quota
43.7%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Accretion Pharmaceuticals Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
100%
Promoter Holding (Post-Issue)
73.14%
Issue Type
Book Building - SME
ISIN
INE0T8T01010
About the Company
Presently our Company is engaged in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder), And Oral Powder (Sachet, Dry Syrup) etc.
Industry Overview
The Indian Pharmaceuticals industry plays a prominent role in the global pharmaceuticals industry. Major segments of Indian Pharmaceutical Industry include generic drugs, OTC medicines, bulk drugs, vaccines, contract research & manufacturing, biosimilars and biologics. India is a global leader in the supply of DPT, BCG, and Measles vaccines. The nation is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and is the leading vaccine manufacturer globally. India also has the highest number of US-FDA compliant Pharma plants outside of USA and is home to more than 3,000 pharma companies with a strong network of over 10,500 manufacturing facilities as well as a highly skilled resource pool. Overview of the Pharmaceuticals Industry: The pharmaceutical industry in India is expected to reach $65 Bn by 2024 and to $130 Bn by 2030. The pharmaceutical industry in India is currently valued at $50 Bn. India is a major exporter of Pharmaceuticals, with over 200+ countries served by Indian pharma exports. India supplies over 50% of Africa's requirement for generics, ~40% of generic demand in the US and 25% of all medicine in the UK. India also accounts for ~60% of global vaccine demand, and is a leading supplier of DPT, BCG and Measles vaccines. 70% of WHO's vaccines (as per the essential Immunization schedule) are sourced from India.
Company History
Accretion Pharmaceuticals was incorporated in the year 2012, our Promoters Harshad Nanubhai Rathod, Vivek Ashok Kumar Patel, Mayur Popatlal Sojitra and Hardik Mukundbhai Prajapati, came together to establish a pharmaceutical manufacturing unit, with vision to provide health care products that match international quality standards at competitive price. Thus, the foundation of "Accretion Pharmaceuticals" was laid down, which was started as a Partnership Firm under the Partnership Act, 1932 ("Partnership Act") in the name and style of "Accretion Pharmaceuticals", pursuant to a deed of partnership dated December 18, 2012. Our manufacturing facility which is currently located at 28 & 29 Xcelon Ind Park 1, B/H, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat 382213, commenced its manufacturing operations in year 2014. Thereafter, pursuant to a resolution passed by the partners of Accretion Pharmaceuticals on October 16, 2023, the Partnership Firm was converted into a Limited Company under Part I (Chapter XXI) of the Companies Act, 2013 in the name of "Accretion Pharmaceuticals Limited" and a certificate of incorporation dated November 29, 2023 was issued by the Registrar of Companies, Central Registration Centre, for and on behalf of the jurisdictional Registrar of Companies.
Growth Strategy
- Improve global presence.
- Leveraging our market skills and relationship.
- Maintaining edge over competitors.
- Customer Satisfaction.
Customer Base
wholesaler and retailer
Financial Performance
Revenue, profit after tax and total assets across the last 2 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a standalone basis, as reported for FY24 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offer of upto 29,46,000 equity shares of face value of Rs. 10/- each (the equity shares) of Accretion Pharmaceuticals Limited (the company or accretion or the issuer) at an issue price of Rs. 101 per equity share for cash, aggregating up to Rs. 29.75 crores (public issue) out of which 1,47,600 equity shares of face value of Rs. 10 each, at an issue price of Rs. 101 per equity share for cash, aggregating Rs. 1.49 crores will be reserved for subscription by the market maker to the issue (the market maker reservation portion). The public issue less market maker reservation portion i.e., issue of 27,98,400 equity shares of face value of Rs. 10 each, at an issue price of Rs. 101 per equity share for cash, aggregating upto Rs. 28.26 crores is herein after referred to as the net issue. The public issue and net issue will constitute 26.50% and 25.17% respectively of the post-issue paid-up equity share capital of our company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Experienced Promoters and Management Team.
- Consistently supplying quality products to our valued customers in time.
- Continually improving the quality standards by implementing process control and prevention techniques.
- Long-standing relationship with clients and suppliers.
- Quality standards.
- A significant portion of its revenue is derived from exports, and any decline in export profitability may adversely impact its overall financial performance.
- The Company operates in pharmaceutical sector, which is extensively regulated, any failures on the company part to comply with the existing and future statutory and/or regulatory requirements in the pharmaceutical sector could adversely affect its business, results of operations and financial condition.
- Its manufacturing units are subject to periodic inspections and audits by regulatory authorities and clients. Its may be subject to regulatory action which may damage the company reputation leading to an adverse effect on its business, results of operations, financial condition and cash flows.
- The company has a very limited operating history as a Company, which may make it difficult for investors to evaluate its historical performance or future prospects.
- The company has only one Manufacturing Facility, continued operations of its manufacturing facility is critical to the company business and any disruption in the operation of its manufacturing facility may have a material adverse effect on the company business, results of operations and financial condition.